anyone got two Janoshik results on the same GGPeps lot for this
transit-times.csv
700 rows · not retained in the public archive
#cagrilintide 2026-06-20
Saturday46 messages9 participantstimes are UTC
Highlights from this day
- surpass_two — dosing them on different days made no difference i could detect 16:47
- VialBot — Inter-lab diff for lot A-2418: 99.4% vs 96.8%. Within expected range. 17:15
- half_life_hal — coming back to this amylin analogue, so its not a GLP-1 at all right 17:17
- bea_reconstitutes — monotherapy was underwhelming for me and i say that as someone who wanted it to work, i could be wrong 17:45
- homa_ir_hugo — whats the recon people use, 30 in 2.5ml 19:32
different not less
🧪1
slower than the others
you cannot tell which of the two is doing what in a combination and i stopped pretending i could
fullness rather than nausea
amylin is about slowed gastric emptying and satiety signalling, thats the short version and im no pharmacologist
combination for me
⚠️6
titrating dead slow
the fullness effect hasnt faded over 22 months, unlike my semaglutide appetite curve
🔥11
the combination is the thing with trial data behind it, monotherapy in here is mostly us guessing
added it to an existing retatrutide dose rather than starting both, which made attribution possible, someone check my working
the fullness thing is the part people describe differently, food stops being interesting rather than repellent
cant separate them
€72 for a 30 vial and it lasts me longer than the GLP-1 does at my doses
🧪2
i said earlier this year that monotherapy did nothing for me, and at a higher dose it did something
genuine question noticed something around week 26 on monotherapy, well after i had given up expecting to
dosing them on different days made no difference i could detect
👀2🔥5❤️10
did the combination change your GI compared to the GLP-1 alone
cagrisema thats it
separate days
anyone stopped the GLP-1 and kept only this
€72 for a 15 vial and it lasts me longer than the GLP-1 does at my doses
😂1👀2🤝7
Inter-lab diff for lot A-2418: 99.4% vs 96.8%. Within expected range.
🤝8😂12
coming back to this amylin analogue, so its not a GLP-1 at all right
❤️3📉10💀9
is anyone running this on its own or is it all CagriSema in here
monotherapy was underwhelming for me and i say that as someone who wanted it to work, i could be wrong
👀10❤️14📈8
if youre used to GLP-1 titration steps this feels absurdly cautious and i still do it that way
changed my mind on this, i started thinking amylin was the interesting bit and now i think its the pairing
does amylin do something about fullness that the GLP-1 doesnt
the reason nausea reads differently is timing, mine arrived on the second day rather than the first, from memory
CagriSema is cagrilintide with semaglutide and REDEFINE is the trial programme around it
nobody should copy my schedule, im describing it because people asked what a slow ramp looks like
underwhelming honestly
held mine a while
the slower titration in here is community habit as much as anything, the trials had their own schedule
whats REDEFINE testing exactly
REDEFINE is the trial
peptidemeter-summary-kp-0925.pdf
2 pages · 773 KB · not retained in the public archive
anyone holding at 0.5 for a while before stepping
[edited]went slower because the first step gave me two rough days and i took that as information
whats the recon people use, 30 in 2.5ml
❤️16
how many weeks before you noticed anything on monotherapy
is the weekly schedule the same here
thats the phase 3 one
🧪10
quick one dropped the GLP-1 and stayed on this alone for 14 months, appetite held but weight barely moved
fridge-temps.csv
397 rows · not retained in the public archive
the numbers everyone quotes come from the combination, so comparing them to monotherapy logs is unfair
amylin not glp-1